title: President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do?
authors.affiliation: a American Osteopathic Academy of Addiction Medicine , P.O. Box 3278, Oak Brook , Illinois , 60523 ; www.aoaam.org.
authors.forename: William R
authors.initials: WR
authors.lastname: Morrone
mesh_terms: D000281:Administration, Intranasal; D017277:Drug Approval; D062787:Drug Overdose / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D009270:Naloxone / Q000008:administration & dosage / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D053610:Opiate Alkaloids / Q000506:poisoning*; D010344:Patient Advocacy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D009292:Narcotic Antagonists; D053610:Opiate Alkaloids; D009270:Naloxone